longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

SttStrtSPDRS&PUSHlthCareSelectSectETF

SSEHF

----
Start trading
OverviewOverviewNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends
LongbridgeAI
  • Weekly Recap | Gilead Sciences -4.82%, most brokers rate it buy

    Weekly Review·13 hours ago
    GILD-0.75%
  • Weekly Recap | Abbvie +0.26%, most brokers rate it buy

    Weekly Review·14 hours ago
    ABBV+0.83%
  • Weekly Recap | Abbott Laboratories -5.89%, most brokers rate it buy

    Weekly Review·14 hours ago
    ABT-1.36%
  • Weekly Recap | Unitedhealth -4.54%, near one-month low

    Weekly Review·14 hours ago
    UNH-2.37%UNHU-4.58%
  • Weekly Recap | TMO.US -0.65%, most brokers rate it buy

    Weekly Review·14 hours ago
    TMO+1.10%
  • Weekly Recap | Merck -4.26%, most brokers rate it buy

    Weekly Review·15 hours ago
    MRK-0.54%
  • Weekly Recap | Eli Lilly -2.93%, closing $3.8 billion deal

    Weekly Review·15 hours ago
    LLY-0.65%LLYX-1.72%
  • Weekly Recap | Intuitive Surgical +0.67%, most brokers rate it buy

    Weekly Review·15 hours ago
    ISRG+2.41%ISUL+4.73%
  • Weekly Recap | Johnson & Johnson -3.51%, consensus target above spot

    Weekly Review·15 hours ago
    JNJ-0.29%
  • Weekly Recap | Amgen -13.7%, most brokers rate it hold

    Weekly Review·15 hours ago
    AMGN-1.34%
  • Weekly Recap | Unitedhealth +1.07%, most brokers rate it buy

    Weekly Review·Sep 5 at 08:26 AM
    UNH-2.37%UNHU-4.58%
  • Weekly Recap | Merck +1.33%, most brokers rate it buy

    Weekly Review·Sep 5 at 07:25 AM
    MRK-0.54%
  • Weekly Recap | Eli Lilly -2.15%, most brokers rate it buy

    Weekly Review·Sep 5 at 07:19 AM
    LLY-0.65%LLYX-1.72%
  • Weekly Recap | Johnson & Johnson +2.68%, closing in on record highs

    Weekly Review·Sep 5 at 07:11 AM
    JNJ-0.29%
  • Weekly Recap | Abbvie +0.38%, positive Phase 3 myeloma data

    Weekly Review·Sep 5 at 06:00 AM
    ABBV+0.83%